OncoMatch/Clinical Trials/NCT06276491
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Is NCT06276491 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies XmAb541 for ovarian cancer.
Treatment: XmAb541 — The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Endometrial Cancer
Testicular Germ Cell Tumor
Biomarker criteria
Required: CLDN6 expression
Demographics
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate kidney function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Stanford · Palo Alto, California
- University of California · San Francisco, California
- Moffitt Cancer Center · Tampa, Florida
- Winship Cancer Institute, Emory University · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06276491 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require CLDN6?
Yes, CLDN6 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages